Education
About Us
Working with TipRanks
Follow Us
Prenetics Group (PRE)
NASDAQ:PRE
Top Page
Prenetics Group
(NASDAQ:PRE)
Rating:54Neutral
Price Target:
$9.00
▲(12.50%Upside)
Prenetics Group (PRE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$104.27M
Dividend YieldN/A
Average Volume (3M)72.36K
Price to Earnings (P/E)―
Beta (1Y)0.69
Revenue Growth85.33%
EPS Growth30.70%
CountryUS
Employees285
SectorHealthcare
Sector Strength39
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.80
Shares Outstanding11,453,009
10 Day Avg. Volume119,884
30 Day Avg. Volume72,359
Financial Highlights & Ratios
PEG Ratio0.56
Price to Book (P/B)0.69
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/Revenue0.67
Enterprise Value/Gross Profit4.41
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$14.00Price Target Upside75.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Prenetics Group Business Overview & Revenue Model
Company DescriptionPrenetics Global Limited, an investment holding company, operates as a diagnostics and genetic testing company. Its products include CircleDNA, a consumer genetic testing product; and Circle HealthPod, a rapid detection health monitoring system that allows users to take COVID-19 tests at point-of-care or at home utilizing the nucleic acid amplification test. The company's products also comprise ColoClear, a non-invasive FIT-DNA colorectal cancer screening test; Circle SnapShot, an off-the-shelf at-home blood test; Circle Medical, a diagnostic testing product; and Circle One and F1x/Fem. Prenetics Global Limited was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.
How the Company Makes MoneyPrenetics Group generates revenue through a diversified business model that includes direct-to-consumer sales, partnerships with healthcare providers, and corporate wellness programs. Key revenue streams include the sale of genetic testing kits, which offer insights into ancestry, health risks, and personalized nutrition plans. The company also earns money by providing diagnostic services, such as COVID-19 testing, to governments, airports, and large organizations. Significant partnerships with healthcare institutions and businesses enhance its distribution channels and expand its market reach, contributing to its overall earnings.
Prenetics Group Financial Statement Overview
Summary
Prenetics Group shows strong cost management with a gross profit margin of 50%. However, persistent negative EBIT, net income margins, and negative cash flows indicate profitability challenges and cash flow issues. The balance sheet is stable with low leverage, but overall financial performance needs improvement to ensure long-term viability.Income Statement
Prenetics Group has seen fluctuating revenue growth, with recent declines from 2022 to 2023 but a recovery in 2024. Gross profit margin stands at roughly 50%, indicating strong cost management. However, negative EBIT and net income margins highlight ongoing profitability challenges that could impact long-term sustainability.35
Negative
Balance Sheet
The company maintains a strong equity position with a positive equity ratio, indicative of low leverage and financial stability. The debt-to-equity ratio remains low, though high negative net income affects return on equity. Overall, the balance sheet suggests a relatively stable financial footing but with profitability concerns.55
Neutral
Cash Flow
Operating cash flow remains negative, suggesting challenges in generating cash from operations. Despite this, there is a positive trend in cash flow from investing activities. The free cash flow remains negative, impacting the company's ability to finance operations without external funding. Overall, cash flow management needs improvement.40
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.62M | 21.74M | 275.76M | 275.85M | 65.18M |
| Gross Profit | 15.40M | 8.83M | 131.55M | 106.13M | 26.34M |
| EBITDA | -51.57M | -47.90M | -214.28M | -157.70M | -1.42M |
| Net Income | -46.30M | -62.72M | -190.45M | -174.02M | -1.96M |
Balance Sheet | |||||
| Total Assets | 213.57M | 254.17M | 307.98M | 148.51M | 78.88M |
| Cash, Cash Equivalents and Short-Term Investments | 62.81M | 72.74M | 164.20M | 45.19M | 14.49M |
| Total Debt | 5.77M | 2.37M | 6.65M | 5.27M | 1.67M |
| Total Liabilities | 42.23M | 44.01M | 67.94M | 549.40M | 47.88M |
| Stockholders Equity | 170.39M | 206.36M | 237.06M | -400.81M | 31.08M |
Cash Flow | |||||
| Free Cash Flow | -29.94M | -14.68M | 8.17M | 2.00M | -5.94M |
| Operating Cash Flow | -28.87M | -13.76M | 14.51M | 13.42M | -2.88M |
| Investing Cash Flow | 38.54M | -82.95M | -46.14M | -22.02M | -5.97M |
| Financing Cash Flow | -3.34M | -4.70M | 143.32M | 29.32M | 11.84M |
Prenetics Group Technical Analysis
Neutral
8.00
Price Trends
7.26
Positive
5.86
Positive
5.41
Positive
Market Momentum
0.23
Positive
49.40
Neutral
32.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Neutral. The current price of 8 is below the 20-day moving average (MA) of 8.14, above the 50-day MA of 7.26, and above the 200-day MA of 5.41, indicating a neutral trend. The MACD of 0.23 indicates Positive momentum. The RSI at 49.40 is Neutral, neither overbought nor oversold. The STOCH value of 32.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
Our securities may be delisted from NASDAQ as a result of our failure of meeting the NASDAQ continued listing requirements. Q4, 2023
2.
Our securities may be prohibited from being traded in the United States under the Holding Foreign Companies Accountable Act in the future if the PCAOB is unable to inspect or investigate completely auditors located in China. The Holding Foreign Companies Accountable Act, as amended by the Consolidated Appropriations Act, 2023, decreased the number of "non-inspection years" from three years to two years, and thus, reduced the time before our securities may be prohibited from trading or delisted. The delisting of our securities, or the threat of them being delisted, may materially and adversely affect the value of your investment. Q4, 2023
3.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we are incorporated under the laws of the Cayman Islands, we conduct substantially all of our operations, and a majority of our directors and executive officers reside, outside of the United States. Q4, 2023
Prenetics Group Peers Comparison
Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $104.27M | ― | -26.74% | ― | 85.33% | 30.70% | |
52 Neutral | $76.24M | ― | 138.92% | ― | 64.15% | 41.65% | |
48 Neutral | $36.59M | ― | -37.15% | ― | -0.26% | 60.09% | |
46 Neutral | C$194.28M | -4.22 | -8.60% | 2.64% | 13.54% | -1.44% | |
43 Neutral | $39.81M | ― | -1454.41% | ― | 35.76% | 47.48% | |
41 Neutral | $11.34M | ― | -127.82% | ― | -24.04% | 84.11% | |
41 Neutral | $5.46M | ― | -809.29% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
PRE
Prenetics Group
8.00
2.02
33.78%
VNRX
VolitionRX
0.74
0.13
21.31%
BNGO
BioNano Genomics
3.37
-29.86
-89.86%
BNR
Burning Rock Biotech
3.40
-2.62
-43.52%
BDSX
Biodesix
0.27
-1.32
-83.02%
MYNZ
Mainz Biomed B.V.
1.43
-17.65
-92.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.